Infusion of a high number of CD34+cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation

被引:15
作者
Ashihara, E [1 ]
Shimazaki, C [1 ]
Okano, A [1 ]
Hatsuse, M [1 ]
Okamoto, A [1 ]
Shimura, K [1 ]
Takahashi, R [1 ]
Sumikuma, T [1 ]
Inaba, T [1 ]
Fujita, N [1 ]
Murakami, S [1 ]
Haruyama, H [1 ]
Nakagawa, M [1 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Med 2, Kyoto, Japan
关键词
CD34+cells; autologous PBSCT; economic analysis; hematopoietic recovery;
D O I
10.1093/jjco/hyf030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The objectives of this study were to evaluate the effect of the number of infused CD34+ cells on hematopoietic recovery and on the cost in autologous peripheral blood stem cell transplantation (PBSCT). Methods: Sixty-nine patients who received autologous PBSCT (ABSCT) were divided into three groups defined by the number of infused CD34+ cells. The number of days until 0.5 x 10(9)/l neutrophils and 50 x 10(9)/l platelets, the number of transfused blood products, the febrile days, the duration of parenteral antibiotics and the cost of additional supportive care (transfusions of blood products and parenteral antibiotics) were analyzed. Results: Twenty-three patients received <2.5 x 10(6)/kg of CD34+ cells (group A), 25 patients received greater than or equal to2.5 to 5 x 106/kg of CD34+ cells (group B) and 21 patients received greater than or equal to5 x 10(6)/kg of CD34+ cells (group C). Patients in group C had rapid neutrophil (p < 0.01) and platelet (p < 0.05) recovery and required less platelet transfusions (p < 0.05) than patients in other groups. Transfusions of red blood cell concentrates, the duration of febrile days or parenteral antibiotics were not statistically different between the two groups. The patients in group C required significantly lower costs for platelet concentrates and additional supportive care (p < 0.05). Conclusion: Infusion of greater than or equal to5 X 10(6)/kg of CD34+ cells in ABSCT shortens hematopoietic recovery and reduces costs for additional supportive care.
引用
收藏
页码:135 / 139
页数:5
相关论文
共 21 条
[1]  
Ashihara E, 2000, HAEMATOLOGICA, V85, P1112
[2]   SUBSETS OF CD34(+) CELLS AND RAPID HEMATOPOIETIC RECOVERY AFTER PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION [J].
DERCKSEN, MW ;
RODENHUIS, S ;
DIRKSON, MKA ;
SCHAASBERG, WP ;
BAARS, JW ;
VANDERWALL, E ;
SLAPERCORTENBACH, ICM ;
PINEDO, HM ;
VONDEMBORNE, AEGK ;
VANDERSCHOOT, CE ;
GERRITSEN, WR .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1922-1932
[3]  
Duncan N, 1996, BONE MARROW TRANSPL, V18, P1175
[4]   CD34+/CD41+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation [J].
Feng, R ;
Shimazaki, C ;
Inaba, T ;
Takahashi, R ;
Hirai, H ;
Kikuta, T ;
Sumikuma, T ;
Yamagata, N ;
Ashihara, E ;
Fujita, N ;
Nakagawa, M .
BONE MARROW TRANSPLANTATION, 1998, 21 (12) :1217-1222
[5]  
GALE RP, 1992, BONE MARROW TRANSPL, V9, P151
[6]   Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy [J].
Glaspy, JA .
BONE MARROW TRANSPLANTATION, 1999, 23 (Suppl 2) :S21-S27
[7]   PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATIONS - PAST, PRESENT AND FUTURE [J].
HENON, PR .
STEM CELLS, 1993, 11 (03) :154-172
[8]   Relationship of CD34(+) cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation [J].
Kiss, JE ;
Rybka, WB ;
Winkelstein, A ;
deMagalhaesSilverman, M ;
Lister, J ;
DAndrea, P ;
Ball, ED .
BONE MARROW TRANSPLANTATION, 1997, 19 (04) :303-310
[9]   Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery [J].
Remes, K ;
Matinlauri, I ;
Grenman, S ;
Itala, M ;
Kauppila, M ;
Pelliniemi, TT ;
Salminen, E ;
Vanharanta, R ;
Rajamaki, A .
JOURNAL OF HEMATOTHERAPY, 1997, 6 (01) :13-19
[10]   Stem cell mobilisation in lymphoproliferative diseases [J].
Russell, NH ;
McQuaker, G ;
Stainer, C ;
Byrne, JL ;
Haynes, AP .
BONE MARROW TRANSPLANTATION, 1998, 22 (10) :935-940